CA 15-3
Also known as: Cancer Antigen 15-3
What Does CA 15-3 Measure?
CA 15-3 (Cancer Antigen 15-3) is a blood test that measures the level of a protein called MUC1, a mucin glycoprotein that is shed from the surface of cells, particularly breast cancer cells, into the bloodstream. This protein is naturally present on the surface of many types of cells, but cancer cells — especially breast cancer cells — tend to overproduce and release much higher amounts of it. The test detects and quantifies how much of this protein is circulating in the blood at a given time.
Why Does CA 15-3 Matter?
CA 15-3 is primarily used as a tumor marker for breast cancer, though it is not used for initial diagnosis or routine screening. Its greatest clinical value lies in monitoring patients who have already been diagnosed with breast cancer, particularly to track how well treatment is working, detect early signs of disease recurrence, or assess the extent of metastatic spread. Elevated levels are associated with more advanced or metastatic breast cancer, and rising values over time may indicate disease progression or treatment failure. Notably, CA 15-3 can also be elevated in other cancers (such as ovarian, lung, and colon cancers) and certain benign conditions, so results must always be interpreted in the context of a full clinical evaluation.
Normal Ranges
Males
Less than 30 U/mL
Females
Less than 30 U/mL (some labs use <25 U/mL as the upper limit)
Children
Not routinely measured in children; adult reference ranges may apply if clinically indicated
Causes of High Levels
- Metastatic or advanced breast cancer — the most common cause of significantly elevated levels
- Other cancers including ovarian, lung, colon, pancreatic, and liver cancers
- Benign breast conditions such as fibrocystic breast disease or mastitis
- Liver diseases including cirrhosis, hepatitis, or other hepatic disorders
- Benign ovarian cysts or endometriosis
- Pregnancy and lactation, which can cause mild physiological elevations
Causes of Low Levels
- Successful treatment of breast cancer leading to reduced tumor burden
- Complete surgical removal of breast cancer tissue (e.g., mastectomy)
- Effective response to chemotherapy or targeted therapy in breast cancer patients
How to Improve Your CA 15-3
Diet
- Follow an anti-inflammatory, plant-rich diet with abundant cruciferous vegetables (broccoli, cauliflower, Brussels sprouts) that contain cancer-fighting compounds like sulforaphane
- Limit processed meats, refined sugars, and ultra-processed foods that promote systemic inflammation
- Incorporate omega-3-rich foods such as wild-caught salmon, flaxseeds, and walnuts to support immune function
- Consume phytoestrogen-rich foods like soy in moderation — discuss with your oncologist, as this remains nuanced for hormone-sensitive cancers
- Maintain a healthy body weight through a balanced diet, as obesity is associated with worse breast cancer outcomes
Supplements
- Vitamin D3 (1,000–4,000 IU/day as tolerated and guided by blood levels) — low vitamin D is associated with poorer breast cancer prognosis; always consult your doctor before supplementing
- Omega-3 fatty acids (EPA+DHA, 1,000–3,000 mg/day) for anti-inflammatory support — discuss with your oncologist as they may interact with some treatments
- Curcumin (500–1,000 mg/day with piperine for absorption) has shown preliminary anti-tumor properties in research but should only be used under medical supervision
Related Biomarkers
Frequently Asked Questions
Can a high CA 15-3 result mean I have breast cancer?
Not necessarily. While elevated CA 15-3 is associated with breast cancer — especially advanced or metastatic disease — it is not a diagnostic test for breast cancer. Many benign conditions such as liver disease, benign breast conditions, and even pregnancy can raise CA 15-3 levels. Conversely, many people with early-stage breast cancer have normal CA 15-3 levels. A diagnosis of breast cancer requires imaging studies, biopsy, and a full clinical evaluation by your doctor.
Why isn't CA 15-3 used to screen for breast cancer?
CA 15-3 is not sensitive or specific enough to be used as a general screening tool for breast cancer. It often remains normal in early-stage disease (low sensitivity), and it can be elevated in many non-cancerous conditions (low specificity). This means it would produce both false negatives (missing real cancers) and false positives (raising alarm in healthy individuals). Mammography, with or without ultrasound or MRI, remains the gold standard for breast cancer screening.
How often should CA 15-3 be monitored in breast cancer patients?
The frequency of CA 15-3 monitoring depends on the stage of your disease and your treatment plan. For patients with known metastatic breast cancer, it is commonly measured every 2–3 months to track treatment response. For patients who have completed treatment for early-stage breast cancer, guidelines vary — some oncologists measure it periodically during follow-up, while others prefer imaging-based surveillance. Always follow the schedule recommended by your individual care team.